These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19583633)

  • 1. Realities of newer beta-blockers for the management of hypertension.
    Manrique C; Giles TD; Ferdinand KC; Sowers JR
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vasodilatory beta-blockers.
    Pedersen ME; Cockcroft JR
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR; Greenberg BH; Weber MA
    Am J Med; 2010 Nov; 123(11):S2. PubMed ID: 21035578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
    Wehland M; Grosse J; Simonsen U; Infanger M; Bauer J; Grimm D
    Curr Vasc Pharmacol; 2012 May; 10(3):378-90. PubMed ID: 22022769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephroprotective properties of third-generation beta-adrenoblockers].
    Kuz'min OB; Belianin VV; Zhezha VV
    Eksp Klin Farmakol; 2014; 77(3):40-3. PubMed ID: 24800526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
    Marazzi G; Volterrani M; Caminiti G; Iaia L; Massaro R; Vitale C; Sposato B; Mercuro G; Rosano G
    J Card Fail; 2011 Sep; 17(9):703-9. PubMed ID: 21872138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA; Bakris GL; Giles TD; Messerli FH
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract]   [Full Text] [Related]  

  • 16. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
    Frishman WH; Henderson LS; Lukas MA
    Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.